While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.
MicroStrategy, the corporate world's largest Bitcoin holder, sees the token's price dip below its average purchase cost for the first time since 2023, testing the resilience of Michael Saylor's high-conviction, leverage-fueled strategy amid a shifting market landscape.
Pzena Investment Management's Focused Value Strategy lagged behind its benchmark in Q4 2025, with semiconductor firm Skyworks Solutions cited as a key detractor. The fund's commentary highlights the challenges for value investing in a market dominated by AI and mega-cap stocks.
The startup, which pivoted from digital business cards, now provides the API infrastructure enabling AI companies to deploy chatbots directly within iMessage, RCS, and SMS, capitalizing on the shift away from traditional apps.
Shares of real estate investment trust Curbline Properties (CURB) have gained momentum, closing recently at $24.25. With reported revenue of $163.7 million and net income of $41 million, the stock appears undervalued by some metrics. However, a sky-high P/E ratio and sector headwinds prompt a closer look at whether the market is pricing in unrealistic growth.
While EOG Resources' stock has lagged behind its energy sector peers, a majority of analysts maintain a bullish stance, betting on the company's disciplined capital returns and operational execution to drive a potential rebound.
Amid a quarter dominated by mega-cap tech and AI fervor, Pzena Investment Management's value-focused fund highlighted discount retailer Dollar General as a key performer, driven by strong earnings that propelled its stock.
Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.
CoinGape has unveiled the winners of its 2025 Crypto Impact Awards, recognizing standout projects, exchanges, and individuals for their tangible contributions to the Web3 ecosystem over a pivotal year. The ceremony highlighted a growing industry focus on execution, regulatory compliance, and measurable user adoption.
Despite a recent 4.7% stock decline, Edwards Lifesciences (NYSE: EW) boasts a robust 13% Return on Equity, outperforming its industry. Yet, its modest 4.6% five-year growth rate raises questions about future potential and market valuation.
Investment firm Curreen Capital posted strong 2025 results, crediting its focus on undervalued 'ugly duckling' stocks. The fund's latest letter spotlights VF Corporation (VFC), the embattled owner of Vans and The North Face, as a potential turnaround play despite its shares falling over 20% in the past year.
Investors who held shares in SouthGobi Resources Ltd. (CVE:SGQ) since 2019 have seen a staggering 486% return, a powerful case study in long-term equity investing despite recent volatility.
While Automatic Data Processing (NASDAQ:ADP) has delivered solid earnings growth over five years, its share price appreciation has notably lagged the broader market. A deeper look reveals dividends have bolstered total returns, but recent underperformance highlights investor caution toward the payroll giant.
Iconic bootmaker Dr. Martens has seen its market value erode by over £80 million, with shares falling 87% over five years. The prolonged decline raises questions about the brand's strategy in a shifting retail landscape.
A surge in sophisticated phishing and social engineering attacks led to a staggering $370 million in cryptocurrency thefts this January, eclipsing losses from technical protocol hacks and signaling a dangerous shift in criminal tactics targeting individual users.
In a strategic reversal, GSK has handed back global rights to the clinical-stage RNA editing drug WVE-006 to Wave Life Sciences. Wave asserts the move allows it to faster advance the potential 'functional cure' for alpha-1 antitrypsin deficiency, while GSK refocuses on broader respiratory markets.
